Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ivonescimab-based combination therapy as first-line treatment for extensive-stage small cell lung cancer
CTR20254070Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- Nov 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in small cell lung cancer (SCLC), sponsored by Akeso, Inc.. Started Nov 2025; status: active.
02
Drugs
ivonescimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20254070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254070.